Shared on 01 Nov 25
Fair value Increased 12%Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.
Shared on 01 May 25
Fair value Increased 8.20%FDA Approval Will Unlock Broad MRI Market Expansion
Shared on 23 Apr 25
Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 2.60%Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Decreased 6.75%Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
AnalystConsensusTarget has decreased revenue growth from 14.7% to 12.8%.